Literature DB >> 28116653

Classical and additional antiphospholipid antibodies in blood samples of ischemic stroke patients and healthy controls.

Narin-Nard Carmel-Neiderman1,2, David Tanne3, Idan Goren3, Pnina Rotman-Pikielny2, Yair Levy4.   

Abstract

Classical antiphospholipid antibodies (aPLa) are found in 6-25% of blood samples from stroke patients. The frequency of novel aPLa antibodies in blood samples of CVA patients is not known. Enzyme-linked immunosorbent assays (ELISA) were performed on blood samples from 209 CVA patients (170 samples were obtained during the acute phase and 39 samples were from patients with complete carotid stenosis) and compared to 54 healthy controls. Subjects were tested for the presence of the classical aPL antibodies anticardiolipin (aCL) and anti-beta2-glycoprotein (aβ2gI), in addition to antiphosphatidylethanolamine (aPE), anti-phosphatidylserine (aPS), and Annexin V. All antibodies were tested for both IgM and IgG subclasses. Numeric analysis of the antibody titer levels (μ/ml) revealed a significantly higher subclinical titer by two standard deviations of many aPL autoantibodies among CVA patients (Pv < 0.05). However, according to the kit manufacturer's cutoff value, no positive antibodies were found except a trend toward higher percentage of positive aPS IgG titer in the CVA group compared to controls (6.2 vs. %0; P = 0.077). According to the manufacturer's cutoff, significantly higher levels of positive antibodies were not found among stroke patients. However, the absolute ELISA values of stroke patients were significantly higher. These results suggest that lower cutoff values than those used for APS diagnosis should be used for risk stratification of CVA among healthy individuals.

Entities:  

Keywords:  APLA; Annexin 5 antibodies; Anti-phosphatidylserine (aPS) antibodies; Anticardiolipin (aCL); Antiphosphatidylethanolamine antibodies (aPE); Aps; Atherosclerotic plaque; Hypercoagulability; Stroke; antieta2-glycoprotein(aβ2gI) antibodies

Mesh:

Substances:

Year:  2017        PMID: 28116653     DOI: 10.1007/s12026-017-8897-z

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  32 in total

1.  Study of phosphatidylserine-dependent anti-prothrombin antibody in cerebral infarction.

Authors:  Hirohisa Okuma; Yasuhisa Kitagawa; Tatsuya Ishikawa; Shigeharu Takagi
Journal:  Intern Med       Date:  2009-08-17       Impact factor: 1.271

2.  Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients.

Authors:  N M Shah; M A Khamashta; T Atsumi; G R Hughes
Journal:  Lupus       Date:  1998       Impact factor: 2.911

3.  High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause.

Authors:  V Toschi; A Motta; C Castelli; M L Paracchini; D Zerbi; A Gibelli
Journal:  Stroke       Date:  1998-09       Impact factor: 7.914

4.  beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program.

Authors:  R L Brey; R D Abbott; J D Curb; D S Sharp; G W Ross; C L Stallworth; S J Kittner
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

Review 5.  Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment.

Authors:  A Tripodi; P G de Groot; V Pengo
Journal:  J Intern Med       Date:  2011-03-11       Impact factor: 8.989

6.  IL-6: an early marker for outcome in acute ischemic stroke.

Authors:  U Waje-Andreassen; J Kråkenes; E Ulvestad; L Thomassen; K-M Myhr; J Aarseth; C A Vedeler
Journal:  Acta Neurol Scand       Date:  2005-06       Impact factor: 3.209

7.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

8.  Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis.

Authors:  Carlos Cantu; Elisa Alonso; Aurelio Jara; Leticia Martínez; Camilo Ríos; María de los Angeles Fernández; Irma Garcia; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-06-10       Impact factor: 7.914

9.  Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.

Authors:  Steven R Levine; Robin L Brey; Barbara C Tilley; J L P Thompson; Ralph L Sacco; Robert R Sciacca; A Murphy; Yimeng Lu; Teresa M Costigan; Candi Rhine; Bruce Levin; Douglas A Triplett; J P Mohr
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

10.  Antiphospholipid antibodies and stroke in young women.

Authors:  Robin L Brey; Christian L Stallworth; David L McGlasson; Marcella A Wozniak; Robert J Wityk; Barney J Stern; Michael A Sloan; Roger Sherwin; Thomas R Price; Richard F Macko; Constance J Johnson; Christopher J Earley; David W Buchholz; J Richard Hebel; Steven J Kittner
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

View more
  3 in total

1.  Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.

Authors:  Jun Sang Yoo; Young Seo Kim; Hyun Young Kim; Hyuk Sung Kwon; Seong-Ho Koh; Sung Hyuk Heo; Bum Joon Kim; Cheryl D Bushnell; Dae-Il Chang
Journal:  J Neurol       Date:  2021-02-06       Impact factor: 4.849

2.  Editorial: Cutting edge in systemic lupus erythematosus.

Authors:  David P D'Cruz; Annegret Kuhn
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

3.  Avidity of anti-phospholipid antibodies in relation to their levels.

Authors:  Lenka FialovÁ; Oliver KuchaŘ; Milada PetrÁČkovÁ; Ivan Malbohan; TomÁŠ Zima
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.